RESUMEN
Euphylong is a theophylline preparation with new galenic slow-release design (micropellets in a capsule), developed for daily single-dose administration in the evening. It has been shown that the majority of patients with bronchial asthma, chronic obstructive bronchitis or emphysema who receive a single evening dose of Euphylong have a theophylline serum concentration that remains within the therapeutic range for 24 hours when the theophylline serum concentration measured at 8 a.m. under steady-state conditions is found to lie within the therapeutic range.
Asunto(s)
Enfermedades Pulmonares Obstructivas/tratamiento farmacológico , Teofilina/administración & dosificación , Adulto , Anciano , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Femenino , Humanos , Enfermedades Pulmonares Obstructivas/sangre , Masculino , Persona de Mediana Edad , Teofilina/farmacocinéticaRESUMEN
Dosage prediction methods for optimization of aminoglycoside therapy were evaluated in 19 critically ill patients. Two different three-point methods and a novel Bayesian method were used. The predictive accuracy and precision of all tested methods were clinically satisfactory. The time needed for the necessary calculations was 10-15 min. After administration of predicted dosages, approximately 90% of the observed peak and trough aminoglycoside serum concentrations fell within the therapeutic range. Without systematic use of these prediction methods, only approximately 40% of tobramycin peak serum concentrations and 80% of trough serum concentrations were within the therapeutic range. Daily dosage adjustments particularly in patients with rapid changes of aminoglycoside clearance are greatly facilitated by use of these prediction methods. These findings suggest that all of the dosage prediction methods tested are well suited for optimization of aminoglycoside dosage regimens.